The present invention provides a binding molecule which is capable of binding to the human NogoA polypeptide or human NiG with a dissociation constant<；1000 nM, a polynucleotide encoding such binding molecule； an expression vector comprising said polynucleotide； an expression system comprising a polynucleotide capable of producing a binding molecule； an isolated host cell which comprises an expression system as defined above； the use of such binding molecule as a pharmaceutical, especially in the treatment of a disease of the peripheral (PNS) and/or central (CNS) nervous system； a pharmaceutical composition comprising said binding molecule； and a method of treatment of a disease of the peripheral (PNS) and/or central (CNS) nervous system.
